Skip to main content
SpringerLink
Log in

Newer antiobesity drugs underprescribed in US

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Thomas CE, et al. Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity (Silver Spring, Md.) 24: 1955-1961, No. 9, 29 Aug 2016. Available from: URL: http://dx.doi.org/10.1002/oby.21533.

    Article  Google Scholar 

  2. Kyle TK, et al. Low utilization of obesity medications: What are the implications for clinical care? Obesity (Silver Spring, Md.) 24: 1832, No. 9, 29 Aug 2016. Available from: URL: http://dx.doi.org/10.1002/oby.21566.

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Newer antiobesity drugs underprescribed in US. PharmacoEcon Outcomes News 762, 29 (2016). https://doi.org/10.1007/s40274-016-3405-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3405-6

Search

Navigation